
08/08/2025
Enrollment is now ongoing in a first-in-human clinical trial testing EPI-321, a therapy designed to target the underlying cause of FSHD. https://buff.ly/h8iZWuv
We are dedicated to sharing the latest news, research, and muscular dystrophy patient perspectives.
5307 E Mockingbird Lane
Dallas, TX
75206
Be the first to know and let us send you an email when Muscular Dystrophy News posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.